Search

The effects of season of growth and monensin treatment on ruminal digestion of fresh-cut autumn and spring pasture were measured in a single group of ruminally fistulated castrated male sheep, housed indoors in metabolism crates. Responses were assessed in terms of ruminal volatile fatty acid molar proportions, ammonia concentration, pH, apparent digestibility of the pasture, and nitrogen balance of the animals. Blood plasma concentrations of insulin, glucose, beta-hydroxybutyrate, urea, and NEFA were also evaluated. Autumn pasture contained significantly lower proportions of water-soluble carbohydrate (P < 0.05), cellulose (P < 0.05), and lignin (P < 0.05) and increased pectin (P < 0.05), hemicellulose (P < 0.05), and crude protein (P < 0.10) concentrations when compared with spring pasture. Voluntary DMI by sheep of autumn pasture was lower (P < 0.01) than that of spring pasture and was significantly (P < 0.05) reduced by monensin treatment. Monensin treatment significantly decreased the ruminal molar proportions of acetic acid (P < 0.10) and butyric acid (P < 0.001) and increased the molar proportions of propionic acid (P < 0.001) and minor VFA (P < 0.01). Nitrogen retention of the sheep was significantly (P < 0.05) reduced by monensin treatment. Plasma glucose levels were increased (P < 0.10) by monensin treatment during the fourth 5-d collection period in both seasons. Chemical analysis suggested that the composition of autumn pasture was different from that of spring pasture and that this was manifested in vivo by increased DMI and digestibility of spring vs autumn pasture. Ruminal fermentation of autumn pasture also had an increased acetate-to-propionate ratio compared with spring pasture. Monensin treatment acted consistently across seasons by increasing the proportion of propionate and decreasing the proportion of acetate in ruminal fluid.

Previous studies have implied that myonuclei accumulation in a muscle is more important than myofibre number in the determination of muscle size in fetal/neonatal lambs. However, due to the lack of a reliable marker, the role of myogenic precursor nuclei (satellite cells) in myofibre hypertrophy in late fetal and postnatal life is not well understood. In this study, MyoD was shown to be a useful marker for actively proliferating satellite cells in both fetal and neonatal lambs. MyoD was used to determine whether there were differences in the number of actively proliferating satellite cells between single and twin fetuses/neonates, which may explain at least some of the difference in myofibre size observed near birth. Eighteen single-bearing and 9 twin-bearing Coopworth ewes were randomly assigned to one of three slaughter groups (100, 120 and 140 days of gestation). The remaining ewes were kept on pasture until 20 days postpartum at which time 4 single and 4 twin lambs were sacrificed. Twin fetuses/neonates had lower body weights and muscle weights compared to singles. Lower muscle weights in the twins were associated with smaller myofibre cross-sectional areas and lower total nuclei numbers and myogenic precursor cell numbers per muscle in selected hind-limb muscles. These results indicate that myofibre hypertrophy in late gestation and early postnatal life is related to myogenic precursor cell number which may have important implications for growth potential of the growth-restricted fetus., (Copyright 2001 S. Karger AG, Basel.)

Previous studies have shown that shearing pregnant ewes at mid- or late-pregnancy is associated with an increase in lamb birth weight. The present study was designed to investigate metabolic responses that may underlie this response. Single- and twin-bearing ewes were either unshorn or shorn at mid-pregnancy (Day 69 of pregnancy; P69), and insulin, glucose and epinephrine challenges were conducted on P109-111 and P132-134. Shearing increased the birth weight of twin lambs by over 1 kg (P < 0.001) without having any effect on singleton birth weight. This response was associated with a 10-20% reduction in the insulin response to a glucose challenge (P < 0.05) without a change in glucose clearance following either glucose or insulin challenges. The lipolytic response to epinephrine challenge increased as pregnancy progressed, but was not associated with the increased birth weight of twin lambs born to shorn ewes. By late pregnancy, a 25% reduction in maternal IGF-I concentration and a two- to threefold increase in maternal IGFBP-1 concentration (P < 0. 05) associated with shearing were observed. The increase in lamb birth weight associated with mid-pregnancy shearing may have been associated with an increase in the non-insulin dependent uptake of glucose by the placental-fetal unit.

Cellular development of the adductor femoris muscle from twin and single fetuses was studied at 140 days gestation to evaluate the effect of moderate fetal growth retardation on myofibre development. Twin fetuses had lower bodyweights (13%) and disproportionately small adductor femoris muscle weights (22%) compared with single fetuses. Reduced muscle mass was associated with smaller myofibre cross-sectional areas (CSA) and lower DNA content (22%), indicative of fewer myonuclei and retarded myofibre hypertrophy. Myofibre number and the phenotypic maturation of the myofibres were similar between twins and singletons. These results indicate that even modest growth restriction during fetal life can negatively influence myofibre hypertrophy, highlighting the importance of fetal nutrition for muscle growth. Large muscles, such as the adductor femoris, have intrafascicularly terminating myofibres, which necessitates accurate sampling of the muscle when investigating possible perturbations in morphological characteristics (e.g. between singletons and twins). The second objective of the present study was to investigate the impact of the sampling site on the morphological parameters of the adductor femoris muscle. The apparent total myofibre number decreased from the proximal to the distal region of the adductor femoris muscle. The apparent number of slow-twitch fibres also decreased from the proximal to the medial region, but was not different between the medial and distal regions of the muscle. Similarly, myofibre CSA differed between the medial and distal regions. These results indicate that, particularly with large muscles, such as the adductor femoris, which has intrafascicularly terminating myofibres, single site sampling for the determination of morphological fibre characteristics may generate misleading results and that careful selection of the sampling area may be necessary.

Muscle growth, myofibre number, type and morphometry were studied in large hindlimb muscles of single and twin fetal lambs during mid to late gestation. Placental insufficiency, evident by lower total placentome weight and number per fetus, resulted in reduced fetal weights from 100 to 140 days gestation in twins compared with singletons (at 140 days: 5016 +/- 108 g v. 5750 +/- 246 g, respectively; P<0.05). However, competition between littermates did not consistently reduce muscle mass (15-22%) until 140 days gestation. Apparent myofibre number increased with age, indicating that the full complement of myofibres in some large hindlimb muscles may be achieved during early postnatal life. Litter size did not impact on apparent myofibre number in the semitendinosus, plantaris or gastrocnemius muscles. However, a transient effect on myofibre number in the adductor femoris muscle was observed from 80-120 days gestation. The phenotypic maturation of myofibres was unaffected by increasing litter size. Smaller muscle mass in twins was associated with smaller myofibre cross-sectional area in the semitendinosus, adductor femoris and gastrocnemius muscles at 140 days gestation. A similar trend was observed for the plantaris muscle. These results indicate that while competition between littermates for nutrients in late gestation can impact on both fetal and muscle mass, the fetus has the capacity to buffer against the effects of restricted nutrient supply on myofibre hyperplasia and phenotypic maturation, but myofibre hypertrophy is compromised.

The ontogeny of hepatic growth hormone (GH) receptors (GHR), as measured by responses of both plasma insulin-like growth factor-I (IGF-I) and hepatic GHR to an exogenous bGH stimulus, was examined using sheep of different ages (Days 1-7, 14-21, 28-35, and 56-63 of life, and yearlings). The IGF-I response to bGH was first examined in yearling sheep using two doses of bGH (0.1 and 0.2 mg/kg LW/d). Based on these results, lambs in four groups up to Day 63 of life were treated for 5 d with bGH (n = 10) at a dose of 0.15 mg/kg LW/d or with saline (n = 10). Jugular blood samples were taken once daily on Days - 1, 4, and 5 of treatment. bGH treatment in lambs up to Day 63 of life had little effect on plasma concentrations of GH, insulin, glucose or urea, but significantly (P < 0.05) increased circulating concentrations of IGF-I at all ages and of NEFA at Day 62/63 of life. In contrast, bGH treatment at either dose in yearlings significantly increased these parameters, except for plasma urea concentrations which were decreased in bGH-treated yearlings. However, the responses of plasma IGF-I concentration to bGH stimulus in lambs up to Day 63 of life were small compared to those in yearling sheep. Consistent with this, bGH treatment failed to affect hepatic GH binding in young lambs, but up-regulated it in yearling sheep. Furthermore, basal (unstimulated) GH binding did not differ between sheep of 7 vs. 63 vs. 365 d of age, despite the greater IGF-I responses to bGH in the latter group. It is suggested that hepatic GHR in lambs up to Day 63 of life are not fully functional compared to the situation in yearlings.

The effects of recombinant bovine growth hormone (bGH) treatment of pregnant ewes on maternal metabolism, placental development and fetal growth were examined in two studies. In a preliminary study (experiment one), single-bearing ewes were treated by twice-daily subcutaneous injection for 7 days with bGH (n = 8) at a dose of 0.15 mg/kg LW/day or with saline (n = 8) between days 101 and 107 of gestation inclusive. In experiment two, single- and twin-bearing ewes were treated for 14 days with bGH (0.15 mg/kg L W/day) (n = 10) or saline (n = 10) between days 70 and 83 or days 98 and 111 of gestation inclusive. Ewes were killed on the day following termination of bGH treatment and fetal and placental measurements recorded. Maternal plasma concentrations of GH, IGF-I and insulin were higher (P < 0.001) in bGH-treated ewes relative to saline-treated ewes in both experiments. Consistent across experiments was an increase (P < 0.05) in the weight of the myoendometrium in bGH-treated ewes. Treatment with bGH also increased the total weight of the gravid uterus (P < 0.05) in both experiments. Weights of the uterine fluids were increased by bGH in experiment one (P < 0.05), but an effect of the same magnitude could not be repeated in experiment two. In experiment one, there was a tendency towards increased mean fetal body weights after growth hormone treatment, although the effect was non-significant. In experiment two, treatment with bGH was associated with significantly (P < 0.05) higher fetal weights, but only at the later stage of gestation (day 112). This effect was additive with that of fetal rank. Exogenous bGH treatment had little discernible effect on measures of placental size. It is concluded that administration of exogenous bGH to pregnant ewes can stimulate fetal growth, but only after about day 100 of gestation. This response seems most likely to reflect changes in maternal nutrient partitioning or placental function, rather than placental size. These studies suggest a role for growth hormone of maternal or placental origin in the regulation of fetal growth.

The ability of ovine placental lactogen (oPL) to bind to the growth hormone receptor (GHR) raises the possibility that oPL may exert a growth hormone (GH)-like action on galactopoiesis. We have compared the effects of treating lactating ewes for 5 days with an equimolar dose (0.1 mg/kg/day, administered as two equal doses 12 hourly) of either bovine growth hormone (bGH) (n = 10), oPL (n = 10) or saline (n = 9) on hepatic and mammary GHR, insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) gene expression and hepatic GHR number. Hepatic GHR and IGFBP-3 mRNA were unaltered by bGH or oPL treatment. Hepatic IGF-I mRNAs increased following bGH (P < 0.05) but not oPL treatment. GHR gene expression was greater in liver compared to mammary gland extracts. There was no effect of either bGH or oPL treatment on mammary GHR, IGF-I or IGFBP-3 mRNA or hepatic GHR number. These studies confirm the galactopoietic effects of bGH in lactating ruminants and suggest that the mechanism of this action is not via increased hepatic GHR number or gene expression. In addition, the increase in hepatic but not mammary IGF-I mRNA with bGH treatment suggests an endocrine action of IGF-I on milk synthesis. These studies also demonstrate that an equimolar dose of oPL is not galactopoietic or somatogenic in the lactating ewe.

The effects of recombinant ovine placental lactogen and bovine growth hormone on milk yield, milk composition, and concentrations of blood hormones and metabolites were compared in ewes during an established lactation. Beginning on d 17 of lactation, ewes were treated for 5 d with twice daily subcutaneous injections of ovine placental lactogen (n = 9), bovine growth hormone (n = 10) at a dose of 0.10 mg/d per kg of body weight, or saline (n = 10). Circulating concentrations of ovine placental lactogen were 24.6 +/- 1.6 ng/ml on d 5 for ewes treated with ovine placental lactogen, but concentrations of ovine placental lactogen were undetectable in ewes treated with either saline or bovine growth hormone. Treatment with bovine growth hormone increased circulating concentrations of growth hormone, insulin-like growth factor-I, and nonesterified fatty acids and decreased urea concentrations relative to those in ewes treated with ovine placental lactogen or saline. Compared with saline treatment, no parameters were affected by treatment with ovine placental lactogen. Treatment with bovine growth hormone or ovine placental lactogen treatment had no significant effects on plasma concentrations of insulin, glucose, or creatinine. Treatment with bovine growth hormone, but not ovine placental lactogen, increased yields of milk, fat, and lactose. Weight of the mammary gland was increased by bovine growth hormone, but not by ovine placental lactogen. Despite the fact that ovine placental lactogen is a potent somatogen, it does not appear to exhibit the same galactopoietic activity as bovine growth hormone in lactating ewes.

The objective was to examine myogenesis in two situations expected to be characterized by maternal constraint: (i) in fetuses due to be born in spring (n=10) or autumn (n=10); and (ii) in single (n=16) and twin (n=20) fetal lambs. Maternal constraint operating through limitation of placental size, as measured by placentome weight per fetus, was evident in each study. Although a lower placental weight did not influence body and muscle weights of fetuses due to be born in the spring or autumn, twins had lower body and muscle weights than singles. Fibre number and average fibre cross-sectional (CS) area were differentially affected by season and fetal number. The differences in muscle fibre morphology between spring- and autumn-born fetuses suggest that muscle fibre development was influenced by maternal constraint in the absence of an effect on fetal weight. The differences in muscle fibre number and CS area in particular muscles from twin and single fetuses suggest that more severe maternal constraint, reflected in a lower placental size per fetus, not only influences fetal weight but can also affect muscle development.

Previous studies involving fetal decapitation or hypophysectomy, and the treatment of neonates with hormones or antibodies, have suggested that changes in pituitary hormone status during the perinatal period may influence later body composition. In the present study, rats were treated for the first 21 days of life with twice daily subcutaneous injections of saline, recombinant bovine growth hormone (bGH) or pituitary ovine prolactin (oPRL). The bGH and oPRL were administered at doses of 0.2 or 0.4 microgram/g bodyweight/day. One-third of the rats in each treatment group were slaughtered at each of days 21, 60 and 120 of life and measurements made of: length and weight of the body; weights of bones and muscle groups in the hindlimb; weights of four fat depots (120-day group only); and the content of nitrogen (N) and fat in the carcass. bGH, but not oPRL, treatment increased weight of the femur and humerus (across ages) but neither treatment had marked effects on weights of muscle groups, carcass weight or carcass N content at any age. Both bGH and oPRL treatment significantly reduced weight of the subcutaneous scapular fat depot and reduced carcass fat content, but only in animals aged 120 days (i.e. 99 days after the cessation of treatment). It is concluded that treatment of rats with bGH and oPRL during the immediate postnatal period specifically retards the ability of animals to deposit body fat in later life by mechanisms which differ from those involved in the classical lipolytic/antilipogenic effects of bGH.

The growth-promoting and metabolic effects of recombinant ovine placental lactogen (oPL) were compared with those of recombinant bovine growth hormone (bGH) in young lambs. Lambs were treated by twice daily subcutaneous injection with oPL (n = 16) or bGH (n = 16) at a dose of 0.1 mg/kg live weight/day or with saline (n = 16) for 21 days commencing on day 3 of life. Jugular blood samples were taken on days 0, 10 and 20 of treatment. Half the lambs in each group were slaughtered at 24 days, and the other half at 9 months of age. Both bGH and oPL treatments induced small but significant (P < 0.05) increases in circulating concentrations of insulin-like growth factor-I (IGF-I) on day 10 of treatment, but not on day 20. Neither treatment altered plasma concentrations of glucose, non-esterified fatty acids, urea or creatinine compared to those in saline-treated lambs. Relative to those of bGH-treated (0.24 +/- 0.01 kg/day) or saline-treated (0.25 +/- 0.01 kg/day) lambs, live weight gains of oPL-treated lambs (0.28 +/- 0.01 kg/day) were significantly (P < 0.05) increased during treatment and differences in live weight were still apparent at 9 months of age. Similarly, treatment with oPL, but not bGH, significantly (P < 0.01) increased daily energy intake. It is concluded that placental lactogen and growth hormone do not have identical biological actions. While oPL is growth-promoting in young lambs, this effect may be mediated by stimulating voluntary feed intake rather than by elevating circulating concentrations of IGF-I.

The role of placental lactogen (PL) in the regulation of maternal metabolism and fetal growth is not understood. Both PL and growth hormone (GH) have been suggested as possible regulators of mammogenesis. Our aim was to compare the effects of recombinant ovine placental lactogen (oPL) and bovine growth hormone (bGH) on maternal mammary gland development and fetal growth. Pregnant ewes were treated from day 101 to 107 of gestation with twice daily subcutaneous injections of recombinant oPL (n = 7), bGH (n = 8) (0.15 mg/kg live weight/day) or saline (n = 8). On day 108 of gestation, fetal and maternal tissues were collected. The relative abundance of growth hormone receptor (GHR), insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) mRNA was assessed in mammary gland, maternal liver and heart, and in fetal and placental tissues. There was no detectable change in mammary tissue GHR, IGF-1 or IGFBP-3 gene expression with either bGH or oPL treatment. Maternal administration of bGH, but not oPL, during pregnancy caused an increase in maternal hepatic IGF-1 gene expression (P < 0.005). Treatment with oPL, but not bGH, resulted in a significant increase (P < 0.025) in the relative abundance of fetal hepatic IGFBP-3 mRNA. Maternal hepatic GHR gene expression was not affected by treatment. This study suggests that while bGH treatment of pregnant ewes induces characteristic somatogenic responses, oPL treatment does not have comparable effects. However, oPL may indirectly influence the fetal somatotropic axis by altering fetal hepatic IGFBP-3 production.

We have shown previously that chronic administration (8 weeks) of insulin-like growth factor-I (IGF-I) has little growth-promoting effect in well fed sheep. The aim of this study was to investigate the anabolic effects of IGF-I in energy-restricted conditions in which circulating concentrations of IGF-I in control animals were expected to be low. Young castrate male sheep were offered chaffed lucerne at a rate equivalent to 110% maintenance and were treated by sc injection three times per day for either 8 or 12 weeks with recombinant human IGF-I (150 micrograms/kg live wt x day) or saline in a 2 x 2 factorial design (eight animals per cell). IGF-I treatment significantly increased plasma IGF-I concentrations, but reduced plasma concentrations of IGF-II, GH, urea, and creatinine. Treatment with IGF-I also decreased (P < 0.1) GH secretion in response to a GRF load, but significantly (P < 0.05) increased the nonesterified fatty acid response to an epinephrine load. The reduction in circulating GH levels was accompanied by a suppression of [125I]oGH binding to hepatic microsomal membranes. This effect, if apparent in other tissues, may act as a feedback mechanism to limit the local synthesis of IGF-I and could explain why IGF-I treatment had little effect on the growth rate of the sheep, although it did increase nitrogen digestibility of the feed consumed and decreased the fat content of the hind leg. It also differentially promoted the growth of the spleen, thymus, and mandibular salivary gland and increased blood counts of eosinophils. It is concluded that IGF-I does not have marked effects on growth rate or body composition in sheep fed a near-maintenance diet. Possible reasons include the associated suppression of GH secretion and action, which limits the ability of treated animals to repartition absorbed nutrients.

Although insulin-like growth factor-binding protein-2 (IGFBP-2) is an abundant IGFBP in fetal and postnatal plasma, its regulation is not yet clearly understood. To address this question in sheep, we purified ovine IGFBP-2 and developed a homologous radioimmunoassay. We have studied its ontogenesis and measured serum concentrations of ovine IGFBP-2 after bovine growth hormone (bGH), ovine placental lactogen (oPL) and IGF-I treatment. Concentrations of IGFBP-2 were high at 125 days of gestation (550 +/- 15 micrograms/l) but fell after birth (P < 0.05) and plateaued after 1 year of age (340 +/- 20 micrograms/l). In lactating ewes, bGH treatment for 7 days significantly reduced (21%; P < 0.05) IGFBP-2 relative to the saline-treated group. Similarly, in neonatal lambs, bGH treatment from day 3 to day 23 of life reduced (P < 0.05) IGFBP-2 by 23% relative to the saline-treated group. oPL had no effect on serum levels of IGFBP-2 in the ewe or the neonatal lamb. In well-fed yearling lambs, treatment with IGF-I reduced IGFBP-2 values by 27% (P < 0.05) relative to control animals. In yearling lambs, reduced nutrition increased plasma IGFBP-2 (41%; P < 0.05). However this increase was abolished by IGF-I treatment. The changes in plasma levels of IGFBP-2 were positively related to changes in IGF-II while there was a negative relationship between circulating IGF-I and IGFBP-2 such that both IGF-I and IGF-II may play a role in the regulation of IGFBP-2 in serum.

The role of insulin-like growth factor I in the regulation of fetal growth was investigated in two lines of mice selected for high or low concentrations of this factor in plasma. In Expt 1, females from each line were mated with males of the reciprocal line to generate fetuses of equivalent genotype. Females with low concentration of the factor in plasma exhibited the typical negative relationship between mean fetal mass and litter size (b = -0.032 +/- 0.006 g per fetus, P < 0.01). However, dams of the line with high concentrations of the factor did not exhibit this relationship (b = -0.004 +/- 0.006 g per fetus), despite the fact that they had 26% larger litters (P < 0.05) at a common maternal body mass. This difference in maternal constraint apparently reflects a greater capacity for nutrient transfer to the fetuses in the dams with more insulin-like growth factor I in plasma, as suggested by the absence of a relationship between mean placental mass and mean fetal mass in that line. In Expt 2, the effect of fetal genotype for insulin-like growth factor I was investigated by transferring embryos of the two lines into females of an unrelated strain. Fetuses from the line with high concentrations of the factor in plasma were heavier at term (1.51 versus 1.37 g, pooled SE = 0.05 g, P < 0.05) than fetuses from the line with low concentrations in plasma. It is therefore concluded that fetal growth is influenced by both the maternal and fetal genotypes for insulin-like growth factor I, but in qualitatively different manners.

Fetal growth is normally constrained by maternal factors. This constraint is demonstrated by the usual inverse linear relationship between litter size and mean fetal weight. Cross-breeding experiments between mice of lines selected for high or low plasma insulin-like growth factor (IGF-I) levels suggested that elevations in maternal IGF-I abolish (P less than 0.01) this constraining effect and reverse the usual positive relationship between fetal and placental size in late gestation. This was confirmed by treating mice and rats throughout pregnancy with IGF-I. In normal mice and in low IGF-I line mice treatment with IGF-I (10 micrograms 8-hourly s.c. from day 1 to 19 of pregnancy) abolished maternal constraint whereas 0.9% (w/v) NaCl treatment did not. In Wistar rats osmotic pumps were implanted to deliver IGF-I (1 microgram/g body weight per day), bovine GH (bGH; 0.6 microgram/g body weight per day) or saline from day 1 to 19 of pregnancy. IGF-I therapy but not bGH or saline abolished (P less than 0.01) maternal constraint and altered (P less than 0.01) the relationship between placental and fetal weight. When high or low IGF-I line mice embroys were transplanted into a normal line of mice, the expected negative relationship (P less than 0.05) between mean fetal weight and litter size was maintained. However, the embryos of the high line were heavier (P less than 0.05) than those from the low line irrespective of fetal number, suggesting a direct role for IGF-I in the regulation of fetal growth.(ABSTRACT TRUNCATED AT 250 WORDS)

Castrate yearling male sheep were treated for 8 weeks with either 50 micrograms/kg body wt/8 hourly sc insulin-like growth factor-I (IGF-I) (n = 10) or with saline (n = 9). IGF-I treatment increased plasma IGF-I from 235 +/- 17 to 347 +/- 16 ng/ml (P less than 0.001). There was a gradual divergence in body wt (P less than 0.10) between treatment groups. Food intake did not change significantly. The weight of the spleen corrected for body wt increased by 40% (P less than 0.001) and there was a marginal increase in adjusted kidney wt (P less than 0.1). There was no effect of IGF-I on carcass weight or dimensions, or on long bone length, although the weight per unit length of the tibia (P less than 0.05) and femur (P less than 0.10) were increased. There was no effect on wool growth. Plasma IGF binding proteins (IGFBPs) were quantified by ligand blot analysis. In the IGF-I treated group, IGFBP-1 showed a transient increase (P less than 0.05) at day 3 but was similar in both groups at day 55 of treatment. IGFBP-2 was suppressed (P less than 0.05) by day 55 and IGFBP-3 and 4 did not change. Plasma glucose was elevated (P less than 0.05) and plasma insulin was suppressed (P less than 0.01) from 280 +/- 32 pg/ml to 124 +/- 30.4 pg/ml, plasma urea (P less than 0.01) and creatinine (P less than 0.05) were reduced in the IGF-I treated group. The somatogenic effect of IGF-I in this study was minimal suggesting that in the well fed animal with an intact somatotropic axis IGF-I treatment at doses which double plasma IGF-I does not enhance somatic growth performance. However, the marked splenomegaly shows the sensitivity of splenic growth to systemic IGF-I. The suppression of insulin with chronic IGF-I treatment was accompanied by hyperglycaemia--this may explain in part the lack of a significant anabolic response and may limit the utility of IGF-I therapy unless higher doses with insulin-like effects are used.

In castrated rams (Romney and Poll Dorset, n = 8 for each breed), inhibition by testosterone treatment (administered via Silastic capsules) of luteinizing hormone (LH) pulse frequency, basal and mean LH concentrations, mean follicle-stimulating hormone (FSH) concentration, and the peak and total LH responses to exogenous gonadotrophin-releasing hormone (GnRH) were significantly (P less than 0.01) greater during the nonbreeding than during the breeding season. Poll Dorset rams were less sensitive to testosterone treatment than Romney rams. In rams not receiving testosterone treatment, LH pulse frequency was significantly (P less than 0.05) lower during the nonbreeding season than during the breeding season in the Romneys (15.8 +/- 0.9 versus 12.0 +/- 0.4 pulses in 8 h), but not in the Poll Dorsets (13.6 +/- 1.2 versus 12.8 +/- 0.8 pulses in 8 h). It is concluded that, in rams, season influences gonadotrophin secretion through a steroid-independent effect (directly on hypothalamic GnRH secretion) and a steroid-dependent effect (indirectly on the sensitivity of the hypothalamo-pituitary axis to the negative feedback of testosterone). The magnitude of these effects appears to be related to the seasonality of the breed.

Growth allometry was examined over the range 6 to 112 days of age in male and female mice from lines selected for low (L) or high (H) plasma concentrations of insulin-like growth factor-I (IGF-I). Plasma IGF-I concentrations were greater in the H line than in L line mice from 28 days of age. H line mice also had greater liveweights and weights of the heart, kidneys, pancreas, lungs, liver, brain and testes from 21-28 days of age. Changes in weights of these organs reflected the general pattern of body growth, there being no consistent effects of selection line on allometric growth coefficients. Ovarian weights were not different between the lines. For muscle weights, (gastrocnemius, quadriceps femoris), the weights or lengths of bones (tibia, femur) and the nose-anus and anus-tail lengths, allometric growth coefficients were generally higher (P less than .05) in L line females than in L line males or H line mice of either sex. The allometric growth coefficient for spleen was significantly (P less than .05) greater in H line mice than in L line mice with the result that spleen weights were 30% higher in H line mice from 28 days of age. This is consistent with results from mice treated with, or transgenic for, IGF-I and suggests a specific effect of this hormone on growth of the spleen. Thymus weights were also greater in H line than in L line mice and developmental patterns of thymus weight closely paralleled those of circulating IGF-I.

We evaluated the interrelationship between, and regulation of, the hepatic growth hormone receptor and serum GH binding protein (GH BP) in pigs treated with recombinant porcine growth hormone (rpGH). Infant and pubertal male pigs (N = 5 per group) received either rpGH 0.15 mg/kg daily or diluent intramuscularly for 12 days. Somatic growth, serum IGF-I and GH BP and [125I]bovine GH (bGH) binding to MgCl2-treated hepatic membrane homogenates were examined. Marked age-related increases were seen in serum GH BP (p less than 0.001) and [125I]bGH binding to hepatic membranes (p less than 0.001). GH BP was increased in rpGH treated animals (p = 0.03), from 13.8 +/- 1.2 (mean +/- 1 x SEM) (controls) to 17.8 +/- 2.0% in infants, and from 35.2 +/- 2.6 (controls) to 41.8 +/- 3.4% in pubertal animals. [125I]bGH binding to hepatic membranes was also increased by rpGH treatment (p less than 0.05), from 7.0 +/- 1.6 (controls) to 15.4 +/- 3.6% in infants and from 53.7 +/- 7.1 (controls) to 65.1 +/- 11.8% in pubertal animals. No significant interaction between age and treatment was seen. Overall, serum GH BP correlated significantly with [125I]bGH membrane capacity (r = 0.82, p less than 0.001), with a correlation of r = 0.83 in the infant animals but no significant correlation in the pubertal animals considered alone (r = 0.13). Serum IGF-I correlated significantly with serum GH BP (r = 0.93, p less than 0.001) and [125I]bGH membrane binding capacity (r = 0.91, p less than 0.001). These observations suggest that serum GH BP levels reflect major changes of hepatic GH receptor status.(ABSTRACT TRUNCATED AT 250 WORDS)

Basal hormone/metabolite concentrations and responses to intravenous challenges of glucose, insulin and epinephrine were examined in Friesian cows from selection lines of low or high genetic merit treated with recombinantly-derived bovine somatotropin (bST) or control formulation in a 2 x 2 factorial design. Cows from the low genetic merit (low breeding index, LBI) line had previously been shown to be more responsive to the galactopoietic effects of bST (50 mg/day) than those from the high breeding index (HBI) line. Despite this, comparisons of metabolic differences were not confounded by differences in energy balance because bST treatment had also caused an increase in voluntary intake of cut pasture. Circulating levels of somatotropin, insulin-like growth factor-I (IGF-I) and insulin were greater in bST-treated than control cows but neither bST treatment nor selection line influenced basal concentrations of glucose, non-esterified fatty acids (NEFA), beta-hydroxybutyrate, urea or creatinine. Treatment with bST produced a small increase in sensitivity of cows to the lipolytic effects of epinephrine and this effect was similar in both selection lines. HBI cows had greater circulating insulin levels following the glucose challenge than LBI cows but bST treatment did not affect the insulin response to exogenous glucose. Whereas bST treatment retarded the glycogenolytic response to epinephrine and the clearance of blood glucose in response to insulin in LBI cows, it had no effect on epinephrine-stimulated glycogenolysis, and caused enhanced glucose clearance in response to insulin, in HBI cows. Results are consistent with bST altering the homeorhetic control of metabolism but do not adequately explain the greater responsiveness of LBI cows to the galactopoietic effects of bST.

The physiological responses to somatotropin supplementation of ruminants are reviewed with particular reference to the dairy industry. Exogenous somatotropin improves lactational performance by altering the partitioning of absorbed nutrients. Lipid accretion is reduced, lipid mobilization is increased, and glucose uptake by peripheral tissues and whole body oxidation of glucose and amino acids are reduced. The net effect of these changes is that the limited supply of glucose and amino acids is spared for synthesis of milk components, and lipid reserves are preferentially used as an energy source. The increase of cardiac output and mammary blood flow are prominent physiological responses to somatotropin by the dairy cow. These responses permit a greater share of nutrient input to the mammary gland. The lack of evidence for functional membrane receptors for somatotropin in mammary tissue demands the involvement of endocrine mediators to explain the increase of mammary gland metabolism with somatotropin treatment. An increase of high affinity somatotropic receptors in the liver and increased plasma insulin-like growth factor-I and -II appear to be one of the most prominent endocrine responses to somatotropin treatment. However, the relative role of the insulin-like growth factors and the multiple forms of their plasma-binding proteins and receptors remain to be resolved.

A study was undertaken to examine the ontogeny of circulating insulin-like growth factor-1 (IGF-1) concentrations in sheep. The trial was a balanced 2 x 2 factorial design incorporating the effects of sex and rearing rank with a total of 48 animals. Blood sampling was initiated four weeks post-weaning (about 3 months of age) and continued every 2 weeks for 6 months and then every 4 weeks for 7 months. Fecal egg counts and plasma concentrations of non-esterified fatty acids (NEFA) were also determined. IGF-1 concentration was positively related to live weight throughout the trial, even when adjusted to common sex and rearing rank. Sex of lamb had a significant effect on plasma IGF-1 concentrations with concentrations in males being greater than those in females. Puberty in females, as determined by date of first estrus, was associated with an increase in plasma IGF-1 concentrations. Although puberty in males was not measured, a surge in plasma IGF-1 concentrations around the approximate time of puberty in males resulted in a marked divergence between the sexes which remained throughout the study. Rearing rank did not influence plasma IGF-1 concentrations beyond 7 months of age. Plasma IGF-1 concentrations tended to be negatively associated with plasma NEFA concentrations and fecal egg counts but relationships were only occasionally significant. IGF-1 levels were highly repeatable, concentrations at the first sample being significantly correlated with those at all subsequent samples. Implications of these results in relation to potential use of plasma IGF-1 concentration as a genetic marker for productivity are discussed.

A study was conducted to investigate developmental patterns of plasma concentrations of insulin-like growth factor-I (IGF-I), body growth and body composition in mice from lines selected for seven generations on the basis of low (L) or high (H) plasma IGF-I, and in a random-bred control (C) line. Litter size was standardized to eight individuals with equal sex ratios (as far as possible) within 48 h of birth. Pups were weaned at an average of 21 days and separated on the basis of sex. Blood samples were collected from one male and one female of each litter on days, 21, 42, 63 and 105 for analysis of plasma concentrations of IGF-I. The animals were then killed and analysed for water, fat and crude protein content. The plasma concentration of IGF-I was influenced by line (P less than 0.05) but not by sex. Significant (P less than 0.001) differences in liveweight between mice from L and H lines were first evident at 21 days of age. From 28 until 105 days of age the H line was significantly (P less than 0.001) heavier than both L and C lines, but differences between C and L lines were inconsistent and mostly non-significant. The growth velocity of the H line was significantly greater than that of C or L lines between 14 and 42 days of age, but differences in growth velocities of C compared with L lines were generally non-significant.(ABSTRACT TRUNCATED AT 250 WORDS)

Bovine growth hormone was administered to Holstein cows (late lactation) in a 4 X 4 Latin square design. Treatments were 1) control, subcutaneous injection of placebo, 2) subcutaneous injection of 25 IU growth hormone every 2nd d, 3) daily subcutaneous injection of 25 IU growth hormone, 4) continuous subcutaneous infusion of 25 IU/d growth hormone. Daily profiles of growth hormone in plasma consisted of: 1) a relatively constant concentration averaging 4.5 ng/ml for control, 2) a single peak of 21 to 25 ng/ml followed by a steady decline to baseline for treatments involving daily or alternate day injection (in the latter case concentrations maintained at baseline during the 2nd d after injection), and 3) a relatively constant elevation to 10.6 ng/ml for the continuous subcutaneous infusion. Total growth hormone in plasma increased in proportion to average daily dose of exogenous growth hormone. Milk yield responses in the daily injected and infused groups did not differ and averaged 28% over controls. Gross efficiency (milk energy/consumed energy) was increased 16% by daily administration of 25 IU growth hormone. Responses to the alternate day injection were approximately half those predicted for an average dose of 12.5 IU/d. No particular pattern in plasma growth hormone concentration need be attained to achieve lactational response to exogenous growth hormone. However, extending the interval between injections beyond 24 h may diminish the response per unit of growth hormone injected.

Bovine growth hormone was administered to four Holstein cows (late lactation) in a Latin square. Treatments were 1) control, subcutaneous injection of placebo, 2) subcutaneous injection of 25 IU growth hormone on alternate days, 3) daily subcutaneous injection of 25 IU growth hormone, and 4) continuous subcutaneous infusion of 25 IU/d growth hormone. Intravenous challenges of epinephrine and thyrotropin-releasing hormone were administered separately on the 1st d after a 12-d interval of growth hormone treatment. Baseline concentrations of nonesterified fatty acids in plasma were not affected by growth hormone treatment. However, release of nonesterified fatty acids to epinephrine challenge was positively related to amount of growth hormone in plasma during treatment and was correlated with milk fat yield and milk energy secretion. Growth hormone release following thyrotropin-releasing hormone was negatively related to amount of growth hormone in plasma during treatment. Release of prolactin to thyrotropin-releasing hormone challenge was not related to average daily dose of exogenous growth hormone. The galactopoeitic action of growth hormone may be partly attributable to its effects on responsiveness of adipose tissue to a lipolytic stimulus but apparently is not associated with changes of pituitary sensitivity to thyrotropin-releasing hormone. Results are consistent with growth hormone functioning as a homeorhetic control of nutrient partitioning.

A divergent selection experiment with mice, using plasma concentrations of insulin-like growth factor-1 (IGF-1) at 42 days of age as the selection criterion, was undertaken for 7 generations. Lines were not replicated. To obtain sufficient plasma for the IGF-1 assay, blood from four individuals was volumetrically bulked to obtain a litter mean IGF-1 concentration. This necessitated the use of between family selection. Although inbreeding accumulated in a linear fashion in each of the high, control and low lines, the rates were different for each line (3.6, 1.6 and 5.3% per generation for the high, control and low lines, respectively). As a consequence, the effects of selection and inbreeding are confounded in this experiment. Divergence between the high and low lines in plasma concentrations of IGF-1 continued steadily until generation 5. In generations 6 and 7, there was a reduced degree of divergence and this contributed towards the low realized heritability value of 0.15 +/- 0.12. Six-week liveweight showed a steady positive correlated response to selection for or against plasma concentrations of IGF-1 until generation 4 (high-low difference = 1.7 g = 12%). In generation 5, a substantial drop in 6-week liveweight in the low line relative to both the high and control lines occurred (high-low difference, 3.9; g, 25%). This difference was maintained until generation 7.(ABSTRACT TRUNCATED AT 250 WORDS)

Four Holstein cows were utilized in a Latin square design with a factorial arrangement of treatments to examine the interaction between effects of dry matter intake (107 vs. 78% of energy requirements) and postruminal infusions (water vs. 395 g/d casein) on lactational performance, utilization of nitrogen and energy, and plasma concentrations of hormones. Yields of milk and milk protein were decreased by feed restriction and increased by casein infusion with no treatment interactions. Restricting feed intake decreased total nitrogen intake by 143 g/d and resulted in smaller quantities of fecal, absorbed, urinary, milk, and retained nitrogen compared with cows fed ad libitum. Casein infusion increased total nitrogen intake (55 g/d), absorbed nitrogen (54 g/d), urinary nitrogen excretion (28 g/d), and milk nitrogen (13 g/d). Casein by dry matter intake interactions were not significant for nitrogen utilization. Restricting feed intake increased plasma growth hormone and decreased concentrations of insulin and triiodothyronine. Glucagon, prolactin, and thyroxine were not affected by intake. Casein infusion did not affect growth hormone, insulin, prolactin, triiodothyronine, or thyroxine. Increased milk and milk protein yields obtained with casein infusion were apparently not mediated through changes in circulating concentrations of these hormones; however, plasma glucagon was increased by casein infusions.

Eight Holstein cows were used to investigate the effects of DM intake and sodium bicarbonate on lactational performance and concentrations of hormones and metabolites in plasma. Cows were fed a diet with or without 1.0% sodium bicarbonate (dry matter basis) in a switchback design. Four cows were fed ad libitum and four cows were fed approximately 80% of their recommended nutrient requirements by restriction of DM intake throughout the three 21-d periods. Supplementing the diet with sodium bicarbonate increased DM intake of cows fed ad libitum. There was a feed intake by sodium bicarbonate interaction for production of 4% FCM. This interaction may be explained by the difference in DM intake of cows fed ad libitum or restricted amounts of feed and supplemented with sodium bicarbonate. Cows fed restricted amounts of feed had lower milk, milk fat, milk protein, milk SNF, and milk energy yields. Restriction of feed intake increased plasma concentrations of somatotropin and nonesterified fatty acids but decreased concentrations of insulin, triidothyronine, thyroxine, glucagon, and prolactin. In contrast, feeding supplemental sodium bicarbonate did not affect concentrations of hormones or metabolites in plasma at either feed intake.

Reproductive performance, mammary gland weight and plasma concentrations of insulin-like growth factor-1 (IGF-1) were examined in 18-day-pregnant mice from lines divergently selected on the basis of plasma IGF-1 concentration. Females of the high IGF-1 (H) line were 14% heavier than those of the low IGF-1 (L) line at mating but did not differ in conception rate during a 15-day mating period. H-line females produced significantly larger litters by an average of 1.5 fetuses (19%), heavier fetuses (7%), greater total fetal weight (30%), heavier placental discs (15%), greater total placental weight (35%) and heavier mammary glands (18%). Plasma IGF-1 values were 12% greater in H-line than L-line females at Day 19 of gestation but the line difference was not significant. It is concluded that differences between the lines in litter size and mammary gland weight are most likely due to differences in maternal bodyweight (which are in turn a consequence of selection for plasma IGF-1 at puberty). Whether the difference in fetal weight is a function of fetal capacity to grow in utero or ability of the dam to provide nutrients for fetal growth is yet to be determined.

Milk production is increased in lactating cows treated with bovine somatotropin (bST) because a greater portion of absorbed nutrients are partitioned for milk synthesis. This homeorhetic action may be caused by alterations in response of key tissues to homeostatic signals. To examine this theory, acute metabolic challenges were administered to 8 multiparous Holstein cows (61 +/- 2 days postpartum) receiving daily subcutaneous injections of pituitary-derived bST (26.3 mg) or excipient during two 14-day treatment periods (crossover experimental design). Treatment with bST increased milk yield 12%. Feed intake did not change so that net energy balance decreased (+ .5 vs. -4.3 Mcal/day). Plasma concentrations of nonesterified fatty acids (NEFA) were chronically elevated in bST-treated cows, consistent with energy balance differences. However, baseline concentrations of glucose, insulin, and glucagon in plasma did not differ. On the last 3 days of treatment, individual metabolic challenges were administered via jugular cannulas: epinephrine (700 ng/kg BW), glucose (250 mg/kg BW), insulin (1.0 micrograms/kg BW), and glucagon (175 ng/kg BW). Plasma glucose was reduced after the insulin challenge to a lesser extent during bST treatment. In bST-treated cows, the increase in plasma NEFA in response to epinephrine was greater, and NEFA concentrations were lowered to a greater extent after insulin and glucose challenges. Glucose, insulin, and glucagon removal rates were not altered, nor was plasma glucose response to epinephrine or glucagon challenges. Treatment of lactating cows with bST primarily altered the response of adipose tissue to homeostatic signals which affect lipid metabolism.

The development of hepatic somatotrophic receptors and plasma concentrations of insulin-like growth factor-I (IGF-I) were investigated at five different ages (2, 20, 35, 105 and 165 days) in four male pigs per group. The specific binding of 125I-labelled porcine GH (pGH) to hepatic somatotrophic membranes was very low at 2 days of age (0.53 +/- 0.12%), and increased progressively (P less than 0.01) with advancing age to 3.60 +/- 0.95% at 165 days of age. Specific binding of 125I-labelled bovine GH (bGH) to the same membrane preparations was markedly higher than binding of 125I-labelled pGH; it also showed a distinct developmental increase (P less than 0.01) with age from 4.4 +/- 0.55% at 2 days of age to 24.0 +/- 1.90% at 165 days of age. Plasma concentrations of IGF-I increased significantly (P less than 0.01) from 79 +/- 14.0 micrograms/l at 2 days of age to 610 +/- 64.0 micrograms/l at 165 days of age. Non-linear regression analysis of the competitive binding data using bGH as labelled and unlabelled ligands showed linear Scatchard plots in the three youngest age groups, with an association constant (Ka) of approximately 3.5 litres/nmol. Curvilinear Scatchard plots were observed in the two oldest age groups. The Ka for the higher affinity binding site (approximately 5.0 litres/nmol) was very similar to that for the sole site observed in the younger animals. The Ka of the lower affinity binding site was approximately 0.35 litres/nmol.(ABSTRACT TRUNCATED AT 250 WORDS)

Three experiments were undertaken to examine the degree and causes of variation in plasma concentrations of insulin-like growth factor-1 (IGF-1) in mice. The relationship between IGF-1 concentrations and liveweight was also examined. In all three experiments, a number of non-genetic factors were found to contribute significantly to the variation in IGF-1 concentrations, the most important of these being sex and litter size. In one experiment, where pups from 16 litters were cross-fostered to avoid the confounding of maternal and direct genetic effects, a heritability of 0.40 +/- 0.27 was estimated for plasma IGF-1 concentration at 35 days of age. To examine further the existence of genetic variation in plasma concentrations of IGF-1 and the genetic covariation between plasma IGF-1 levels and other body traits, a selection experiment with mice has been initiated. Moderate to strong phenotypic correlations between IGF-1 concentrations and weight at an early age have been found in all three experiments.

Substantial responses in the 6-week and mature body-weights of mice occurred after 7 generations of selection for or against plasma levels of Insulin-like Growth Factor-1 (IGF-1). Plasma levels of IGF-1 were also significantly different after 7 generations of selection (high line = 85 +/- 2 ng/ml, low line = 58 +/- 2 ng/ml). The average 6-week weight in the line selected for high plasma IGF-1 was 22.5 +/- .2 g compared with 18.5 +/- .2 g in the low plasma IGF-1 line, after 7 generations of selection. The difference between lines was maintained at 20 weeks of age. These data provide further evidence for the roles of IGF-1 in the regulation of somatic growth and as a mediator of a genetic component of growth.

Plasma concentrations of IGF-1 decrease markedly during starvation secondary to a reduction in somatotropic receptors in the liver. We investigated whether IGF-1 administration during starvation in mice inhibits the catabolic state normally observed. Plasma concentrations of IGF-1 in starved mice receiving IGF-1 therapy were similar to values from non-starved mice, whereas bGH treatment failed to increase plasma IGF-1 levels. The degree of weight loss during 36 hours of starvation was reduced (p less than 0.01) by frequent treatment with subcutaneous IGF-1 but not by bGH therapy. The effect was restricted to the period 28 to 36 hours after commencement of the fast. These results suggest that a fall in circulating IGF-1 may play a role in the metabolic adaptation during malnutrition.

Two fragments of human pancreatic growth hormone-releasing factor, hpGRF-(1-24)-NH2 and hpGRF(1-29)-NH2, were administered to lactating dairy cows in separate experiments. Each experiment involved a 4 X 4 Latin square with treatments being intravenous administration of saline (controls) or three doses of releasing factor (500, 1000, and 2000 micrograms). Administration of the 24-amino acid fragment increased plasma growth hormone concentration from baseline 3 ng/ml to peak 14 ng/ml within 10 min. Growth hormone concentrations returned to baseline by 60 min post treatment. The 29-amino acid fragment resulted in greater responses in both peak concentration (30 ng/ml) and persistency (greater than 240 min). Relationships between dose of releasing factor and response in growth hormone release (as measured by area under the response curve) were not consistent in most cows. Responses of concentrations of growth hormone in blood plasma that result from intravenous injection of up to 2000 micrograms of growth hormone-releasing factor (1-29) would not be sufficient to increase milk yield of cows.

A study was undertaken to investigate the role of testosterone in regulating growth and circulating levels of insulin-like growth factor-I in male mice from lines divergently selected on the basis of plasma IGF-I. Controls of each lines were sham-operated at 10 days of age and treated with peanut oil from day 14 to day 70. A second group, which was castrated at 10 days and treated with testosterone enanthate (0.5 micrograms.(g body weight)-1.day-1) from day 14 to 70, did not differ from controls in body weight but had higher plasma IGF-I concentrations. Delaying testosterone therapy until day 42 in a third group retarded growth, with body weights being significantly lower than those of other two groups from days 35 to 56. However, plasma IGF-I levels in this group were not different from those of controls. Effects of line and treatment were additive. It is concluded that the greater pubertal growth of high-line compared to low-line males is not due to greater stimulation of circulating IGF-I by testosterone. Furthermore, testosterone does not appear to influence pubertal growth by acting on circulating levels of IGF-I.

In this review, "productive efficiency" in dairy cows is defined as the yield of milk obtained in ratio to the nutritional costs associated with maintenance, milk synthesis and loss of body condition during lactation. Improvements in efficiency could occur as a result of changes in digestion and nutrient absorption, maintenance requirement, utilization of metabolizable energy for production or nutrient partitioning. Digestibility can be greatly enhanced by appropriate dietary manipulation. Likewise, it may be possible to reduce maintenance requirements and improve the efficiency with which metabolizable energy is used for milk synthesis by manipulation of the pattern of nutrients presented to tissues. However, these factors apparently do not respond to selection for increased milk yield, and little variation is observed among cows. In contrast, individual cows differ substantially in feed intake and in the partitioning of nutrients among body tissues. Techniques associated with genetic engineering and the early prediction of genetic merit have the potential to improve productive efficiency by manipulation of these processes. However, changes in nutrient partitioning and feed intake during lactation are coordinated by a complex network of controls that accommodate the nutrient requirements of each tissue while maintaining homeostatic balance. Future improvements in productive efficiency will therefore depend on our ability to understand the manner in which these controls operate.

We administered bovine growth hormone to six Holstein cows in a Latin square design to study the relationship between dose of growth hormone and response of milk yield. Treatments were 0, 5, 10, 25, 50, and 100 IU/day of pituitary-derived bovine growth hormone administered in once-daily subcutaneous injections. Feed intake and yield of milk and milk components were measured for the last 5 days of each 10-day injection period. Yields of milk, protein, and fat increased in a dose-responsive fashion up to 32, 27, and 46% (for the 100 IU treatment) above control (26.7, .90, and .98 kg/day). Concentration of lactose in milk was not influenced by treatment, but at larger doses of growth hormone, milk fat percent was elevated and protein percent declined. As a result, milk energy secretion in response to 100 IU/day was increased 37% from control (19.2 Mcal/day). Both energy and nitrogen balance decreased with increasing growth hormone. Limited blood samples (timed to coincide with peak concentration of growth hormone postinjection) indicated treatment did not affect concentrations of glucose or insulin in blood plasma but increased concentration of growth hormone. Concentration of nonesterified fatty acids in blood plasma was increased slightly only at the 100 IU/day dose for which energy balance was negative.

The objectives were to determine the effects of daily injection of bovine growth hormone (bGH) on the metabolism of [1-14C]leucine and [1-14C]palmitate and on hormone and metabolite concentrations in growing Hereford heifers. The experimental design was a 28-d single reversal with two 14-d injection periods of placebo or bGH. Energy intake was restricted to a level slightly above maintenance. Injection of bGH did not affect circulating concentrations of glucose, beta-hydroxybutyrate, urea nitrogen, prolactin, triiodothyronine or thyroxine. Plasma concentrations of insulin and nonesterified fatty acids (NEFA) were chronically elevated whereas leucine concentration was chronically decreased after 1 wk of bGH injection compared to placebo injection. Leucine oxidation was lower and whole-body protein synthesis was higher during bGH injection than during placebo injection. There were increases in both total irreversible loss and oxidation of NEFA during bGH injection compared to placebo injection. These results suggest mobilization of stored fatty acids and increased reliance on NEFA to provide energy for cellular processes. The dual and reciprocal effects of bGH on nitrogen and NEFA metabolism demonstrate its role as a homeorhetic regulator, affecting metabolism of several body tissues to support lean body accretion in Hereford heifers at near-maintenance intake of metabolizable energy.